NeOnc Technologies (NASDAQ: NTHI) is scheduled to release topline Phase 2a results for its investigational drug NEO100 on August 12 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE